Cargando…

Early Administration of the Phytocannabinoid Cannabidivarin Prevents the Neurobehavioral Abnormalities Associated with the Fmr1-KO Mouse Model of Fragile X Syndrome

Phytocannabinoids, including the non-addictive cannabis component cannabidivarin (CBDV), have been reported to hold therapeutic potential in several neurodevelopmental disorders (NDDs). Nonetheless, the therapeutic value of phytocannabinoids for treating Fragile X syndrome (FXS), a major NDD, remain...

Descripción completa

Detalles Bibliográficos
Autores principales: Premoli, Marika, Fyke, William, Bellocchio, Luigi, Lemaire, Valerie, Wolley-Roberts, Marie, Bontempi, Bruno, Pietropaolo, Susanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416983/
https://www.ncbi.nlm.nih.gov/pubmed/37566006
http://dx.doi.org/10.3390/cells12151927
_version_ 1785087910669713408
author Premoli, Marika
Fyke, William
Bellocchio, Luigi
Lemaire, Valerie
Wolley-Roberts, Marie
Bontempi, Bruno
Pietropaolo, Susanna
author_facet Premoli, Marika
Fyke, William
Bellocchio, Luigi
Lemaire, Valerie
Wolley-Roberts, Marie
Bontempi, Bruno
Pietropaolo, Susanna
author_sort Premoli, Marika
collection PubMed
description Phytocannabinoids, including the non-addictive cannabis component cannabidivarin (CBDV), have been reported to hold therapeutic potential in several neurodevelopmental disorders (NDDs). Nonetheless, the therapeutic value of phytocannabinoids for treating Fragile X syndrome (FXS), a major NDD, remains unexplored. Here, we characterized the neurobehavioral effects of CBDV at doses of 20 or 100 mg/kg in the Fmr1-knockout (Fmr1-KO) mouse model of FXS using two temporally different intraperitoneal regimens: subchronic 10-day delivery during adulthood (Study 1: rescue treatment) or chronic 5-week delivery at adolescence (Study 2: preventive treatment). Behavioral tests assessing FXS-like abnormalities included anxiety, locomotor, cognitive, social and sensory alterations. Expression of inflammatory and plasticity markers was investigated in the hippocampus and prefrontal cortex. When administered during adulthood (Study 1), the effects of CBDV were marginal, rescuing at the lower dose only the acoustic hyper-responsiveness of Fmr1-KO mice and at both doses their altered hippocampal expression of neurotrophins. When administered during adolescence (Study 2), CBDV at both doses prevented the cognitive, social and acoustic alterations of adult Fmr1-KO mice and modified the expression of several inflammatory brain markers in both wild-type littermates and mutants. These findings warrant the therapeutic potential of CBDV for preventing neurobehavioral alterations associated with FXS, highlighting the relevance of its early administration.
format Online
Article
Text
id pubmed-10416983
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104169832023-08-12 Early Administration of the Phytocannabinoid Cannabidivarin Prevents the Neurobehavioral Abnormalities Associated with the Fmr1-KO Mouse Model of Fragile X Syndrome Premoli, Marika Fyke, William Bellocchio, Luigi Lemaire, Valerie Wolley-Roberts, Marie Bontempi, Bruno Pietropaolo, Susanna Cells Article Phytocannabinoids, including the non-addictive cannabis component cannabidivarin (CBDV), have been reported to hold therapeutic potential in several neurodevelopmental disorders (NDDs). Nonetheless, the therapeutic value of phytocannabinoids for treating Fragile X syndrome (FXS), a major NDD, remains unexplored. Here, we characterized the neurobehavioral effects of CBDV at doses of 20 or 100 mg/kg in the Fmr1-knockout (Fmr1-KO) mouse model of FXS using two temporally different intraperitoneal regimens: subchronic 10-day delivery during adulthood (Study 1: rescue treatment) or chronic 5-week delivery at adolescence (Study 2: preventive treatment). Behavioral tests assessing FXS-like abnormalities included anxiety, locomotor, cognitive, social and sensory alterations. Expression of inflammatory and plasticity markers was investigated in the hippocampus and prefrontal cortex. When administered during adulthood (Study 1), the effects of CBDV were marginal, rescuing at the lower dose only the acoustic hyper-responsiveness of Fmr1-KO mice and at both doses their altered hippocampal expression of neurotrophins. When administered during adolescence (Study 2), CBDV at both doses prevented the cognitive, social and acoustic alterations of adult Fmr1-KO mice and modified the expression of several inflammatory brain markers in both wild-type littermates and mutants. These findings warrant the therapeutic potential of CBDV for preventing neurobehavioral alterations associated with FXS, highlighting the relevance of its early administration. MDPI 2023-07-25 /pmc/articles/PMC10416983/ /pubmed/37566006 http://dx.doi.org/10.3390/cells12151927 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Premoli, Marika
Fyke, William
Bellocchio, Luigi
Lemaire, Valerie
Wolley-Roberts, Marie
Bontempi, Bruno
Pietropaolo, Susanna
Early Administration of the Phytocannabinoid Cannabidivarin Prevents the Neurobehavioral Abnormalities Associated with the Fmr1-KO Mouse Model of Fragile X Syndrome
title Early Administration of the Phytocannabinoid Cannabidivarin Prevents the Neurobehavioral Abnormalities Associated with the Fmr1-KO Mouse Model of Fragile X Syndrome
title_full Early Administration of the Phytocannabinoid Cannabidivarin Prevents the Neurobehavioral Abnormalities Associated with the Fmr1-KO Mouse Model of Fragile X Syndrome
title_fullStr Early Administration of the Phytocannabinoid Cannabidivarin Prevents the Neurobehavioral Abnormalities Associated with the Fmr1-KO Mouse Model of Fragile X Syndrome
title_full_unstemmed Early Administration of the Phytocannabinoid Cannabidivarin Prevents the Neurobehavioral Abnormalities Associated with the Fmr1-KO Mouse Model of Fragile X Syndrome
title_short Early Administration of the Phytocannabinoid Cannabidivarin Prevents the Neurobehavioral Abnormalities Associated with the Fmr1-KO Mouse Model of Fragile X Syndrome
title_sort early administration of the phytocannabinoid cannabidivarin prevents the neurobehavioral abnormalities associated with the fmr1-ko mouse model of fragile x syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416983/
https://www.ncbi.nlm.nih.gov/pubmed/37566006
http://dx.doi.org/10.3390/cells12151927
work_keys_str_mv AT premolimarika earlyadministrationofthephytocannabinoidcannabidivarinpreventstheneurobehavioralabnormalitiesassociatedwiththefmr1komousemodeloffragilexsyndrome
AT fykewilliam earlyadministrationofthephytocannabinoidcannabidivarinpreventstheneurobehavioralabnormalitiesassociatedwiththefmr1komousemodeloffragilexsyndrome
AT bellocchioluigi earlyadministrationofthephytocannabinoidcannabidivarinpreventstheneurobehavioralabnormalitiesassociatedwiththefmr1komousemodeloffragilexsyndrome
AT lemairevalerie earlyadministrationofthephytocannabinoidcannabidivarinpreventstheneurobehavioralabnormalitiesassociatedwiththefmr1komousemodeloffragilexsyndrome
AT wolleyrobertsmarie earlyadministrationofthephytocannabinoidcannabidivarinpreventstheneurobehavioralabnormalitiesassociatedwiththefmr1komousemodeloffragilexsyndrome
AT bontempibruno earlyadministrationofthephytocannabinoidcannabidivarinpreventstheneurobehavioralabnormalitiesassociatedwiththefmr1komousemodeloffragilexsyndrome
AT pietropaolosusanna earlyadministrationofthephytocannabinoidcannabidivarinpreventstheneurobehavioralabnormalitiesassociatedwiththefmr1komousemodeloffragilexsyndrome